AVITA Medical Inc (ASX: AVH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AVITA Medical Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $244.82 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 127.75 million
Earnings per share -0.268
Dividend per share N/A
Year To Date Return 106.63%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AVITA Medical Inc (ASX: AVH)
    Latest News

    A worried man holds his head and look at his computer.
    Healthcare Shares

    Why is the Avita Medical share price crashing 14% today?

    This healthcare share is falling heavily on Tuesday. But why?

    Read more »

    A group of science or medical professionals cheering good news in the lab.
    Share Gainers

    The Avita Medical share price just leapt 17%! What's going on?

    Avita Medical shares are now up a whopping 110% in 2023.

    Read more »

    Man drawing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why Avita Medical, Imugene, Pantoro, and Tietto shares are pushing higher

    These ASX shares are having a good finish to the week. But why?

    Read more »

    Vanadium Resources share price person riding rocket indicating share price increase
    Healthcare Shares

    Why is the Avita Medical share price rocketing 24% today?

    This healthcare share is ending the week on a very positive note. But why?

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Share Fallers

    Why Avita Medical, Delta Lithium, Santos, and Western Africa Resources are dropping

    The S&P/ASX 200 Index (ASX: XJO) is out of form and sinking deep into the red. In afternoon trade, the benchmark…

    Read more »

    Shot of a young scientist looking stressed while conducting medical research in a laboratory.
    Healthcare Shares

    Why did the Avita Medical share price just crash 25%?

    This healthcare share has been hit hard this morning. But why?

    Read more »

    A young couple in the back of a convertible car each raise a single arm in the air whilst enjoying a drive along the road.
    Investing Strategies

    How I'd try to turn $50k in savings into $1 million worth of ASX shares

    It's not so far-fetched to become a millionaire using stocks. Here's one example of how you could achieve the dream.

    Read more »

    Happy healthcare workers in a labs
    Healthcare Shares

    3 ASX healthcare stocks that have more than doubled in a year

    Shareholders of these ASX healthcare stocks are having a party in 2023.

    Read more »

    A middle-aged couple dance in the street to celebrate their ASX share gains
    Opinions

    $50k in savings? Here's how I'd try to turn that into ASX passive income of $2k a month!

    We could do this in just eight years, believe it or not. Check this out.

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Guess which ASX healthcare share is rocketing 20% on an FDA approval

    Shareholders of this healthcare share will be smiling on Thursday!

    Read more »

    happy investor, share price rise, increase, up
    Small Cap Shares

    Broker says these exciting small cap ASX shares have massive upside

    Check out these highly rated small cap ASX shares with major upside potential.

    Read more »

    A man sits uncomfortably at his laptop computer in an outdoor location at a table with trees in the background as he clutches the back of his neck with a wincing look on his face.
    Healthcare Shares

    Here's why the Avita Medical share price is tumbling 20% today

    Shares in the healthcare company are tanking today, despite no fresh news out since last week.

    Read more »

    Frequently Asked Questions

    No, AVITA Medical does not pay dividends at this time.

    AVITA Medical Inc listed on the ASX on 24 June 2020.

    Yes, as well as being listed on the ASX, AVITA Medical Inc is listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AVITA Medical Inc

    AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.

    The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993. 

    RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo. 

    AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    08 Dec 2023 $4.05 $0.18 4.65% 433,151 $3.93 $4.17 $3.93
    07 Dec 2023 $3.87 $0.15 4.03% 113,392 $3.76 $3.88 $3.76
    06 Dec 2023 $3.72 $0.19 5.38% 227,832 $3.65 $3.90 $3.65
    05 Dec 2023 $3.53 $0.14 4.13% 331,558 $3.41 $3.56 $3.39
    04 Dec 2023 $3.39 $0.18 5.61% 109,489 $3.35 $3.40 $3.30
    01 Dec 2023 $3.21 $-0.08 -2.43% 119,552 $3.29 $3.29 $3.20
    30 Nov 2023 $3.29 $-0.01 -0.30% 244,680 $3.31 $3.32 $3.23
    29 Nov 2023 $3.30 $-0.12 -3.51% 265,871 $3.32 $3.35 $3.30
    28 Nov 2023 $3.42 $0.13 3.95% 408,583 $3.40 $3.43 $3.33
    27 Nov 2023 $3.29 $0.03 0.92% 129,442 $3.27 $3.33 $3.24
    24 Nov 2023 $3.26 $-0.06 -1.81% 142,441 $3.35 $3.40 $3.25
    23 Nov 2023 $3.32 $0.20 6.41% 183,289 $3.16 $3.35 $3.16
    22 Nov 2023 $3.12 $-0.36 -10.34% 846,868 $3.16 $3.21 $3.04
    21 Nov 2023 $3.48 $-0.36 -9.38% 584,787 $3.52 $3.57 $3.29
    20 Nov 2023 $3.84 $0.04 1.05% 170,664 $3.89 $3.94 $3.80
    17 Nov 2023 $3.80 $-0.15 -3.80% 154,937 $4.02 $4.02 $3.79
    16 Nov 2023 $3.95 $-0.16 -3.89% 190,000 $4.11 $4.11 $3.92
    15 Nov 2023 $4.11 $0.07 1.73% 178,841 $4.11 $4.22 $4.09
    14 Nov 2023 $4.04 $0.48 13.48% 586,232 $3.93 $4.17 $3.89
    13 Nov 2023 $3.56 $-0.15 -4.04% 290,615 $3.62 $3.62 $3.45
    10 Nov 2023 $3.71 $0.53 16.67% 628,096 $3.45 $3.96 $3.45

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    07 Jun 2023 Louis (Lou) Panaccio Issued 6,175 $26,490
    Issue of securities. RSUs 18,764
    07 Jun 2023 Louis (Lou) Panaccio Issued 2,646 $11,351
    Issue of options.
    07 Jun 2023 Suzanne Crowe Issued 6,175 $26,490
    Issue of securities. 18,764 RSUs
    07 Jun 2023 Suzanne Crowe Issued 2,646 $11,351
    Issue of options.
    07 Jun 2023 Jeremy Curnock-Cook Issued 6,175 $26,490
    Issue of securities. 18,764 RSUs
    07 Jun 2023 Jeremy Curnock-Cook Issued 2,646 $11,351
    Issue of options.
    07 Jun 2023 Jan Reed Issued 2,646 $11,351
    Issue of options.
    07 Jun 2023 Jan Reed Issued 6,175 $26,490
    Issue of securities.
    07 Jun 2023 James Corbett Issued 100,000 $429,000
    Issue of options.
    07 Jun 2023 Cary Vance Issued 7,092 $30,424
    Issue of options.
    07 Jun 2023 Cary Vance Issued 16,549 $70,995
    Issue of securities. 16,549 RSUs
    07 Jun 2023 Robert McNamara Issued 7,092 $30,424
    Issue of options.
    07 Jun 2023 Robert McNamara Issued 16,549 $70,995
    Issue of securities. 16,549 RSUs
    23 Dec 2022 Louis (Lou) Panaccio Exercise 4,350 $8,743
    Conversion of securities. 12,589 - RSUs
    23 Dec 2022 Louis (Lou) Panaccio Buy 4,350 $8,743
    Conversion of securities.
    23 Dec 2022 Suzanne Crowe Exercise 4,350 $8,743
    Conversion of securities. 12,589 RSUs
    23 Dec 2022 Suzanne Crowe Issued 4,350 $8,743
    Conversion of securities. CDIs
    23 Dec 2022 Jeremy Curnock-Cook Exercise 4,350 $8,743
    Conversion of securities. 12,589 - Share rights
    As per announcement on 23/12/2022.
    23 Dec 2022 Jeremy Curnock-Cook Buy 4,350 $8,743
    Conversion of securities.
    23 Dec 2022 Jan Reed Exercise 7,242 $14,556
    Conversion of securities. 18,372 - RSUs
    23 Dec 2022 Jan Reed Buy 7,242 $14,556
    Conversion of securities.
    23 Dec 2022 James Corbett Buy 7,242 $14,556
    Conversion of securities.
    23 Dec 2022 James Corbett Exercise 7,242 $14,556
    Conversion of securities. 5,783 - RSUs
    13 Dec 2022 Louis (Lou) Panaccio Issued 12,589 $26,436
    Issue of securities. 16,939 RSUs
    13 Dec 2022 Louis (Lou) Panaccio Issued 5,395 $11,329
    Issue of options.
    13 Dec 2022 Suzanne Crowe Issued 5,395 $11,329
    Issue of options.
    13 Dec 2022 Suzanne Crowe Issued 12,589 $26,436
    Issue of securities. 16,939 RSUs
    13 Dec 2022 Jeremy Curnock-Cook Issued 12,589 $26,436
    Issue of securities. 16,969 RSUs
    As per announcement on 19-12-2022
    13 Dec 2022 Jeremy Curnock-Cook Issued 5,395 $11,329
    Issue of options.
    13 Dec 2022 Michael Perry Cancelled 13,800 $28,980
    Cancellation of securities.
    13 Dec 2022 Jan Reed Issued 12,589 $26,436
    Issue of securities. 25,614 RSUs
    13 Dec 2022 Jan Reed Issued 5,395 $11,329
    Issue of options.
    13 Dec 2022 James Corbett Issued 226,296 $475,221
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Louis (Lou) James Panaccio Non-Executive ChairmanNon-Executive Director Jul 2014
    Mr Panaccio has served as Non-Executive Chairman of the Board of Directors since July 2014. Mr. Panaccio is a healthcare businessman with extensive experience companies from concept to commercialization. Mr Panaccio possesses more than 35 years of executive leadership experience in healthcare services and life sciences, including more than 25 years of board-level experience. Mr Panaccio is currently a Non-Executive Director of ASX50 company and one of the world's largest medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005.
    Professor Suzanne Crowe Non-Executive Director Jan 2016
    Professor Crowe AO has served as a Non-Executive Director since January 2016. Australian-based, she is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, and Emeritus Professor, Monash University Melbourne, she is currently a Non-Executive Director of Sonic Healthcare Ltd, a large global medical diagnostic company. Past board positions include St. Vincent's Health Australia Ltd (2012-2021), the country's largest not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia (AO) in 2020 in recognition of her services to health, clinical governance, biomedical research, and education. We believe Professor Crowe is qualified to serve on our board of directors based on her technical experience and extensive expertise in supporting companies with their medical and scientific strategies.
    Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
    Mr Curnock Cook has served as a Non-Executive Director of since October 2012. He is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr Curnock Cook brings his decades of international experience to our Board of Directors. Over his career, Mr Curnock Cook has managed in excess of US $1 billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. Mr. Curnock Cook co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. Mr. Curncock Cook has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan, and Australia. In addition to serving on our Board of Directors, Mr Curnock Cook serves on the following boards: International BioScience Managers Ltd appointed March 2000, Bioscience Managers Pty Ltd appointed January 2003, REX Bionics appointed February 2012, Sea Dragon appointed October 2012, Adherium Ltd appointed April 2015, Bioscience Managers UK Ltd appointed August 2017, Marine Department Ltd, appointed on January 2019, JLCC Ltd appointed December 2019, CRiL appointed November 2020 and Humanetix appointed September 2021. We believe Mr. Curnock Cook is qualified to serve on our board of directors based on his extensive experience in the life sciences.
    Dr Michael S Perry Chief Executive Officer Feb 2013
    Mr Perry was appointed Chief Executive Officer and Executive Director in June 2017. He continues to serve in this role. Prior to this appointment, Dr Perry served as a Non-Executive Director commencing in February 2013. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a U.S. affiliate of Switzerland-based Novartis AG. Dr Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early-stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, a life science investment firm managing 41 venture capital funds, based in San Francisco California. Dr Perry serves as a Director of Arrowhead Pharmaceuticals, a public (NASDAQ) development stage company focused on medicines that treat intractable diseases by silencing genes. He is also a Venture Partner at BioScience Managers Pty Ltd.
    Ms Jan Stern Reed Non-Executive Director Jul 2021
    Jan Stern Reed has served as a Non-Executive Director since July 2021. She has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions.
    Mr James Corbett Non-Executive Director Jul 2021
    Mr Corbett was appointed as President and CEO of the Company effective as of September 28, 2022. Mr Corbett served as a Non-Executive Director from July 2021 to September 28, 2022. He has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr Corbett has global commercial and operating experience, serving as an expatriate General Manager of Baxter Japan and later as General Manager and President of Scimed Life Systems Inc. and Boston Scientific International respectively. During his career he has served as CEO of three publicly listed companies; Microtherapeutics Inc (MTIX), ev3 Inc (evvv), Alphatec Spine (ATEC). Mr. Corbett has also led two privately funded companies as CEO: Home Diagnostics Inc. and Vertos Medical.
    Mr Cary Vance Non-Executive Director Apr 2023
    Mr Vance has over 25 years of leadership experience with commercial and operational expertise in the healthcare industry. He is currently the President and Chief Executive Officer of Titan Medical, a position he has held since July 2022. Prior to this appointment, he served as an independent director for Titan Medicals Board of Directors. Previously, Mr Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical and Myoscience. Prior to these roles, he served as President and CEO of Hansen Medical, a publicly held robotics company from 2014 to 2016. Additional executive leadership experience includes roles include at Teleflex, Covidien, and GE Healthcare.
    Mr Robert McNamara Non-Executive Director Apr 2023
    Mr McNamara is an senior executive with over 25 years of experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management. He is currently a member of the Board of Directors and Chair of Audit Committee for Axonics Modulation Technologies and Teknova. Additionally, Mr McNamara is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies Accuray, Somnus Medical Technologies, and Target Therapeutics.
    Mr Mark Andrew Licciardo Company Secretary Mar 2018
    -
    Erin Liberto Chief Commercial Officer
    -
    Andrew Quick Chief Technology Officer
    -
    Mark Andrew Licciardo Company Secretary
    -
    Donna Shiroma General Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    The Vanguard Group, Inc. 5,738,820 4.54%
    Pura Vida Investments, LLC 4,337,590 3.43%
    BlackRock Institutional Trust Company, N.A. 2,341,715 1.85%
    Michael Perry 1,779,235 1.41%
    Thorney Investment Group 1,500,000 1.19%
    Australian Eagle Asset Management Pty Ltd 1,295,235 1.02%
    Geode Capital Management, L.L.C. 1,259,790 1.00%
    Renaissance Technologies LLC 1,192,900 0.94%
    Private Clients of Hub24 904,150 0.71%
    Millennium Management LLC 901,210 0.71%
    Norges Bank Investment Management (NBIM) 855,815 0.68%
    Polar Asset Management Partners Inc. 768,000 0.61%
    Columbia Threadneedle Investments (US) 748,435 0.59%
    XY Capital Limited 706,830 0.56%
    Goldman Sachs International 662,080 0.52%
    Arlene Perry 631,525 0.50%
    MLC Navigator Platform 592,810 0.47%
    Evan Clucas & Leanne Weston 560,535 0.44%
    Caption Management, LLC 534,795 0.42%
    David Deelen 530,605 0.42%

    Profile

    since

    Note